-
公开(公告)号：US11096921B2
公开(公告)日：2021-08-24
申请号：US15160218
申请日：2016-05-20
Applicant: AMOREPACIFIC CORPORATION
Inventor： Byung Gyu Kim , Hyun Woo Jeong , Su Kyung Kim , Si Young Cho , Chan Woong Park , Dae Bang Seo , Wan Gi Kim , Sang Jun Lee
IPC: A61K31/34 , A61K36/258 , A23L33/11 , A23L33/105 , A23L2/52
Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
-
公开(公告)号：US10279076B2
公开(公告)日：2019-05-07
申请号：US15127399
申请日：2015-03-10
Applicant: AMOREPACIFIC CORPORATION
Inventor： Hyun Jung Shin , Jin Kyu Choi , Byung Gyu Kim , Dae Bang Seo
Abstract: The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.
-
公开(公告)号：US20150283110A1
公开(公告)日：2015-10-08
申请号：US14437802
申请日：2013-11-29
Applicant: AMOREPACIFIC CORPORATION
Inventor： Si Young Cho , Dae Bang Seo , Chan Woong Park , Wan Gi Kim , Sang Jun Lee
CPC classification number: A61K31/34 , A23L33/10 , A23V2002/00 , A61K31/05 , A61K31/36
Abstract: The present invention relates to a composition for preventing or treating heart disease, and more particularly, to a composition for preventing or treating heart disease, comprising (+)-syringaresinol. Specifically, (+)-syringaresinol as an active ingredient may exhibit excellent effect of preventing or improving heart disease by promoting SIRT1 expression and suppressing death of cardiomyocytes induced by reactive oxygen species. Accordingly, the composition according to the present disclosure may be used to prevent, improve or treat heart diseases including cardiovascular diseases.
Abstract translation: 本发明涉及用于预防或治疗心脏病的组合物，更具体地说，涉及包含（+） - 丁香胺的心脏病预防或治疗组合物。 具体来说，作为活性成分的（+） - 丁二烯醇可以通过促进SIRT1表达并抑制由活性氧诱导的心肌细胞死亡而表现出优异的预防或改善心脏病的效果。 因此，根据本公开的组合物可用于预防，改善或治疗包括心血管疾病的心脏病。
-
14.发明授权公开(公告)号：US11642387B2
公开(公告)日：2023-05-09
申请号：US17051990
申请日：2019-04-26
Applicant: AMOREPACIFIC CORPORATION
Inventor： Donghyun Cho , Suhwan Kim , Juewon Kim , Chan Woong Park , Dae Bang Seo
IPC: A61K36/258 , A23L33/105 , A61P31/16 , A61K9/00 , A61K31/715
CPC classification number: A61K36/258 , A23L33/105 , A61K9/0053 , A61K31/715 , A61P31/16 , A61K2236/331
Abstract: Disclosed is a composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides as active ingredients, and the ginseng berry polysaccharides exhibit an inhibitory effect on influenza virus activity or infection due to specific ingredients and structures and, specifically, have an excellent inhibitory effect on neuraminidase activity.
-
公开(公告)号：US11154078B2
公开(公告)日：2021-10-26
申请号：US16547898
申请日：2019-08-22
Applicant: Amorepacific Corporation
Inventor： Dae Bang Seo , Heeyoung Jeon , Sun Mi Kim , Donghyun Cho
IPC: A23L2/02 , A23L29/269 , A23L33/105 , A23L2/52
Abstract: The present invention relates to a liquid food composition comprising a Sophora japonica and a broad-leaf bamboo extract, and more particularly, to a liquid food composition including a Sophora japonica extract, a broad-leaf bamboo extract, and xanthan gum. The liquid food composition includes a high content of the Sophora japonica extract while simultaneously ensuring the liquid properties, and thus can be used widely in the field of foods because the liquid food composition is applicable to liquid formulations.
-
Patent Agency Ranking
公开(公告)号：US10555983B2
公开(公告)日：2020-02-11
申请号：US14781146
申请日：2014-03-27
Applicant: AMOREPACIFIC CORPORATION
Inventor： Hyun Jung Shin , Chan Woong Park , Su Hwan Kim , Dae Bang Seo , Wan Gi Kim , Sang Jun Lee
IPC: A61K36/258 , A61K31/704 , A23L33/105 , A23L2/52
Abstract: Provided in the present specification is a composition for brain activation, comprising ginseng fruit extract as an active ingredient. The composition according to the present specification allows an increase in blood flow in the brain and thus has an effect of ameliorating chronic fatigue syndrome. In addition, the composition according to the present specification activates the brain, and as a result, strengthens connectivity strength between the frontal lobe and the occipital lobe and thus has an effect of improving problem-solving accuracy and reducing solving time in the area of cognitive ability. Therefore, the composition according to the present specification can be used as a pharmaceutical composition or a food composition for patients suffering from chronic fatigue syndrome.
-
公开(公告)号：US10022351B2
公开(公告)日：2018-07-17
申请号：US15160239
申请日：2016-05-20
Applicant: AMOREPACIFIC CORPORATION
Inventor： Byung Gyu Kim , Hyun Woo Jeong , Su Kyung Kim , Si Young Cho , Chan Woong Park , Dae Bang Seo , Wan Gi Kim , Sang Jun Lee
IPC: A61K31/34 , A23L2/52 , A61K36/258 , A23L33/11 , A23L33/105
Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
-
公开(公告)号：US09999611B2
公开(公告)日：2018-06-19
申请号：US15160197
申请日：2016-05-20
Applicant: AMOREPACIFIC CORPORATION
Inventor： Byung Gyu Kim , Hyun Woo Jeong , Su Kyung Kim , Si Young Cho , Chan Woong Park , Dae Bang Seo , Wan Gi Kim , Sang Jun Lee
IPC: A61K31/34 , A23L2/52 , A61K36/258 , A23L33/11 , A23L33/105
CPC classification number: A61K31/34 , A23L2/52 , A23L33/105 , A23L33/11 , A23V2002/00 , A61K36/258
Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
-
公开(公告)号：US09913823B2
公开(公告)日：2018-03-13
申请号：US14352444
申请日：2012-10-18
Applicant: AMOREPACIFIC CORPORATION
Inventor： Byung Gyu Kim , Hyun Woo Jeong , Su Kyung Kim , Si Young Cho , Chan Woong Park , Dae Bang Seo , Wan Gi Kim , Sang Jun Lee
IPC: A61K31/34 , A23L1/30 , A61K36/258 , A23L33/11 , A23L2/52 , A23L33/105
CPC classification number: A61K31/34 , A23L2/52 , A23L33/105 , A23L33/11 , A23V2002/00 , A61K36/258
Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
-
公开(公告)号：US09795583B2
公开(公告)日：2017-10-24
申请号：US14437802
申请日：2013-11-29
Applicant: AMOREPACIFIC CORPORATION
Inventor： Si Young Cho , Dae Bang Seo , Chan Woong Park , Wan Gi Kim , Sang Jun Lee
CPC classification number: A61K31/34 , A23L33/10 , A23V2002/00 , A61K31/05 , A61K31/36
Abstract: The present invention relates to a composition for preventing or treating heart disease, and more particularly, to a composition for preventing or treating heart disease, comprising (+)-syringaresinol. Specifically, (+)-syringaresinol as an active ingredient may exhibit excellent effect of preventing or improving heart disease by promoting SIRT1 expression and suppressing death of cardiomyocytes induced by reactive oxygen species. Accordingly, the composition according to the present disclosure may be used to prevent, improve or treat heart diseases including cardiovascular diseases.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.015 seconds)
